Chim Lang is a consultant cardiologist, clinical pharmacologist and Professor of Cardiology at Ninewells Hospital and Medical School, Dundee.He trained in both cardiology and clinical pharmacology in the UK, Malaysia and the US where he was a Merck Fellow at Vanderbilt University, Nashville and a Fulbright Scholar at Columbia University, New York. A Fellow of the Royal College of Physicians of Edinburgh and of London and a Fellow of the American College of Cardiology, Professor Lang sits on the editorial boards of several scientific journals including Cardiovascular Therapeutics (Joint Editor-in-Chief), Heart, Clinical Science (Associate Editor) and Current Clinical Pharmacology . His research takes a multi-disciplinary approach to the understanding of the pathophysiology and pharmacogenetics of cardiovascular diseases and to the development of treatment strategies in patients with cardiovascular diseases. His research interests range from the clinical physiology and pharmacology of neurohormones in cardiovascular diseases to the pathophysiology of peripheral and coronary endothelial.
Lang CC, Stein CM, Brown RM, Deegan R, Nelson R, Wood M, Wood AJJ. Blunted foreram vasodilation to beta2-adrenergic stimulation in normotensive blacks. New Engl J Med 1995; 333: 155-160.
Lang CC, Chomsky DB, Rayos G, Gothard P, Yeoh TK, Stein CM, Wood AJJ, Wilson JR. Effects of sympathoinhibition on exercise performance in heart failure. Circulation 1997; 96: 238-245.
Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-299.
Hirata K, A Kadirvelu , M Di Tullio, S Homma, AM Choy, CC Lang. Coronary Vasomotor Function is Abnormal in First Degree Relatives of Patients with Type 2 Diabetes Mellitus. Diabetes Care 2007; 30:150-3.
Kumiko H, CC Lang, K Amudha, R Sciacca, M Kinjo, K Sugioka, O Ryo, SK Chow, J Yoshikawa, S Homma. Altered Coronary Microvascular Function and Peripheral Endothelial Dysfunction in Young Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism 2007; 56:1904-1909
Lang CC. Karlin P, Haythe J, Tsao L, Mancini DM. Ease of non-invasive measurement of cardiac output coupled with peak VO2 determination can be easily measured at rest and during exercise in patients with heart failure. Am J Cardiol 2007; 99: 404-5.
Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, Donnan PT. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics. 2008 Apr;18(4):279-287.
Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, Donnan PT. A paucimorphic variant in the HMG-CoA Reductase Gene is associated with Lipid Lowering Response to Statin Treatment in Diabetes: A GoDARTS study. Pharmacogenet Genomics. 2008; Dec;18(12):1021-1026
MA ALZadjali, V Godfrey, F Khan, AM Choy, Doney AS, AK. Wong, JR Petrie,, AD Struthers, CC Lang. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in non-diabetic patients with heart failure. J Am Coll Cardiol 2009; Mar 3;53(9):747-53
Lang CC, Karlin P, Hyath J, Lim TK, Mancini DM. Peak cardiac power, measured noninvasively, is a powerful predictor of outcome in chronic heart failure. Circ Heart Fail 2009; 2:33-38.